弥漫性中线胶质瘤的肿瘤微环境与免疫治疗作用:范围综述
本文为范围综述,聚焦H3 K27变异型弥漫性中线胶质瘤(DIPG/DMG)。该瘤种标准治疗后2年总生存率不足10%,传统免疫检查点抑制剂疗效有限。综述总结了分子与空间图谱揭示的瘤内异质性、谱系可塑性和免疫抑制微环境,并探讨替代检查点阻断、CAR-T和病毒免疫治疗等新策略及转化挑战。
要点
- DMG标准治疗后2年总生存率不足10%,亟需新型治疗策略。
- 肿瘤微环境以髓系细胞群、神经元整合和空间异质性niche为特征。
- 非传统免疫治疗如替代检查点阻断、CAR-T和病毒免疫治疗正在探索中。
核心结论
- 传统免疫检查点抑制剂在DMG中疗效有限,需重新审视肿瘤内在与微环境免疫屏障。
- 分子与空间图谱揭示的异质性、谱系可塑性和免疫抑制微环境正推动非传统免疫治疗策略开发。
研究设计与样本
- 范围综述,系统梳理DMG肿瘤微环境与免疫治疗相关文献。
主要发现
- DMG标准治疗后2年总生存率不足10%。
- DMG具有显著瘤内异质性、谱系可塑性和复杂免疫抑制微环境。
- 微环境由多样髓系细胞群、神经元整合和空间上不同的肿瘤niche塑造。
临床怎么用
- 应关注替代检查点阻断、CAR-T和病毒免疫治疗等非传统免疫策略的临床转化。
- 需优化CNS特异性免疫治疗递送并整合患者来源数据至协作临床试验平台。
局限性
- 需完善临床前模型以加速转化研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diffuse midline glioma, H3 K27-altered, formerly known as diffuse intrinsic pontine glioma, (DIPG/DMG) is the most aggressive form of pediatric brain malignancy, with <10% 2-year overall survival after standard of care. The limited success of traditional immune checkpoint inhibitors in pediatric high-grade gliomas, including DMG, has highlighted the urgent need to re-examine the tumor's intrinsic and microenvironmental barriers to immunotherapy. Advances in molecular and spatial profiling have revealed the profound intratumoral heterogeneity, lineage plasticity, and complex immunosuppressive tumor microenvironment characteristic of DMG, which are shaped by diverse myeloid populations, neuronal integration, and spatially distinct tumor niches. These insights are informing the development of non-traditional immunotherapeutic approaches, including alternative checkpoint blockade, chimeric antigen receptor T cells, and viro-immunotherapy strategies, which aim to overcome DMG's unique immune escape mechanisms. We also outline key translational challenges and future directions necessary to accelerate progress, including the refinement of preclinical models, optimization of central nervous system (CNS)-specific immunotherapy delivery, and the integration of patient-derived data into streamlined, collaborative clinical trial platforms.
引用
- Ramsoomair CK, Sarmiento F, Ramsoomair D, et al. Deciphering the tumor microenvironment and role of immunotherapy in diffuse midline glioma: A scoping review. Neuro Oncol. 2026. PMID: 41629217. doi:10.1093/neuonc/noag014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。